Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr. Siegel on the PX-171-003-A1 Carfilzomib Study

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, explains a clinical trial that looked at the newly approved agent carfilzomib.

Dr. Siegel on His Presentation at the 2010 ASH Meeting

March 14th 2011

David S. Siegel, MD, PhD, Chief, Multiple Myeloma at John Theurer Cancer Center, on his presentation at the 2010 American Society of Hematology (ASH) conference.

Dr. Siegel on the Carfilzomib FDA Approval Process

March 14th 2011

Dr. David Siegel from John Theurer Cancer Center on the Carfilzomib FDA Approval Process

Dr. Siegel on the Importance of Bisphosphonates

March 14th 2011

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma

March 9th 2011

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.

ASH 2010: Carfilzomib Shrinks Tumors in More Than One-Third of Pretreated Myeloma Patients

March 9th 2011

Carfilzomib, described as a next-generation protease inhibitor, produced durable responses in patients with multiple myeloma whose disease relapsed after or proved refractory to all available therapies.

ASH 2010: Multiple Benefits Observed for Bortezomib in Newly Diagnosed Myeloma Patients

March 9th 2011

In patients with newly diagnosed multiple myeloma who are candidates for transplant, bortezomib (Velcade) achieved high complete response (CR) rates during induction, delayed disease progression, and improved overall survival (OS).

Bio-Buzz: Advances in the Treatment of Multiple Myeloma

July 6th 2010

Treatment advances focus on the potential use of Bortezomib and Lenalidomide in the front-line setting to improve patients' response rates.

March 2008

June 25th 2010

The Academy delivers the latest news on biotech and oncoloy research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

Lenalidomide (Revlimid) Plus Dexamethasone Compared with Dexamethasone Alone in Patients with Newly Diagnosed Multiple Myeloma

May 25th 2010

In an oral presentation, Jeffrey A. Zonder, MD, Division of Hematology-Oncology, Karmanos Cancer Center, Wayne State University School of Medicine,Detroit, Michigan, reported updated results of SWOG 0232, a study of lenalidomide (Revlimid) plus dexamethasone compared with dexamethasone alone in patients with newly diagnosed multiple myeloma (MM).

50th Annual Meeting of the American Society of Hematology

January 27th 2009

Highlights from the 50th Annual Meeting of the American Society of Hematology.